Syncona, a healthcare company, and Oxford Science, an early-stage venture capital firm, led a £96m Series A round in Beacon Therapeutics, a ophthalmic gene therapy company. “Beacon Therapeutics combines a broad development pipeline, a deep scientific foundation, a strong clinical network, and a highly experienced management team to drive forward a unique late-stage clinical and pre-clinical pipeline. With the 12-month data from our Phase II SKYLINE trial for AGTC-501 expected shortly and two highly innovative and differentiated pipeline assets for prevalent and rare blinding diseases, we are excited to be building a new leader in the ophthalmic gene therapy space,” David Fellows, Beacon Therapeutics CEO.